Clinical trial NCT02402998: Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia
Official title: Eltrombopag as Second Line Therapy in Adult Patients With Primary Immune Thrombocytopenia (ESTIT Study) in an Attempt to Achieve Long-term Remission: a Single Arm Multicenter Phase II Clinical and Biological Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Primacy Immune Thrombocytopenia
Keywords: Primacy immune thrombocytopenia
Adults
Eltrombopag
Long-term remission
Lead sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Sponsor class: OTHER
First posted: 2015-03-31
Enrollment: 55
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A clinical study to evaluate the efficacy of a drug called eltrombopag in adult patients affected of primary immune thrombocytopenia as first treatment to address the disease.

Detailed description: This is a prospective, multicenter phase II trial designed to evaluate the activity of Eltrombopag second line treatment in adult patients with primary Immune Thrombocytopenia (ITP) not responsive or in relapse after a full first line steroids treatment (prednisone or dexamethasone) ± Intravenous Immune Globulin (IVIG).

Eligibility criteria: Inclusion Criteria:

1. Diagnosis of primary ITP;
2. Age ≥ 18 years;
3. Patients are in the new diagnosis or persistent phase of disease (i.e. within month 12 from diagnosis);
4. Patients not responsive or in relapse after a full course of steroid therapy (prednisone 1 mg/kg/d for at least 28 days or 3 cycles of dexamethasone 40 mg/day for consecutive 4 days, according to the GIMEMA ITP0207 trial) ± IVIG;
5. Patients have a platelet count \< 10 x 109/L documented in a single blood cell count;
6. Patients have bleeding symptoms and a platelet count \> 10 \< 30 x 109/L documented in a single blood cell count;
7. Patients have no bleeding symptoms and a platelet count \>10 \< 30 x 109/L in at least 2 blood cell counts at 3 days interval in the week preceding the enrollment with the last count at the day of enrollment;
8. Patients have corticosteroids or IVIG dependence (the need for ongoing or repeated doses administration of corticosteroids or IVIG to maintain a platelet count ≥ 30 x 109/L and/or to avoid bleeding;
9. Written informed consent obtained from the subject;
10. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from time of enrollment until 6 months after the last dose of study treatment;
11. Female subjects of non-childbearing potential may be enrolled in the study; for this study population, non-childbearing potential is defined as current tubal ligation, hysterectomy, ovariectomy or post-menopause; OR
12. Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate contraception for 30 days prior to start of Eltrombopag, has a negative pregnancy test within 14 days of first dose of Eltrombopag, and has agreed to continue adequate contraception during the entire treatment period and for 6 months after completion of the treatment.

Exclusion Criteria:

1. Diagnosis of secondary ITP. As far as patients with immune thrombocytopenia and antiphospholipid antibodies positivity, individuals without a previous thromboembolic event are excluded only if lupus anticoagulant (LAC) is associated with the presence of anticardiolipin (aCL) and aβ2-Glycoprotein I (aβ2GPI) antibodies;
2. Previous treatment with other anti-ITP second line therapies (i.e. Rituximab, Azathioprine, Cyclosporin-A or other); only patients with a previous full course of steroid (see inclusion criteria for definition) ± IVIG are admitted to the study;
3. Previous treatment with any TPO-R agonists;
4. Patients have life threatening bleeding complications;
5. Patients had deep venous thrombosis (DVT) or arterial thrombosis in the 3 months preceding the enrollment;
6. Patients are HIV, HCV, HBsAg positive;
7. Patients with hepatic impairment (i.e. mild, moderate or severe hepatic impairment (Child-Pugh score \> 6);
8. Patients have a well established liver disease that represents a contraindication for the use of Eltrombopag;
9. Patients are unable to respect the 4-hour interval between Eltrombopag and other medications (e.g. antacids), calcium-rich foods (e.g. dairy products and calcium fortified juices), or supplements containing polyvalent cations such as iron, calcium, aluminium, magnesium, selenium, and zinc;
10. Patients are unable to stop medications that are known to cause a drug-drug interaction with Eltrombopag;
11. Subjects meeting any of the following criteria must not be enrolled in an Eltrombopag study:

    * Lactating female.
    * History of another malignancy. Exception: subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
    * Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance with the study procedures.
    * Hormone replacement therapy. Subjects must discontinue hormone replacement therapy prior to study enrollment due to the potential for inhibition of Cytochrome P450 (CYP) enzymes that metabolize estrogens and progestins.
    * Administration of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment.
    * Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to Eltrombopag or excipients that contraindicate their participation.

Primary outcomes:
measure: Number of subjects who achieve long-term response (6 months sustained response) and able to taper down the dose.
timeFrame: After one year from study treatment.
Secondary outcomes:
measure: Number of months of response from eltrombopag discontinuation to the last follow-up.
timeFrame: After one year from study treatment.
measure: Number of months of complete response from eltrombopag discontinuation to the last follow-up.
timeFrame: After one year from study treatment.
measure: Number of bleeding events.
timeFrame: After one year from study treatment.
Other outcomes:
measure: Modification of immunological parameters during treatment and their relationship with clinical outcomes. (Composite outcome)
timeFrame: At baseline, week 24, 36 and 52
measure: Analysis of the relationship between baseline TPO serum level and response to therapy.
timeFrame: After six months from treatment start.
Locations:
city: Bologna
country: Italy
facility: Azienda Ospedaliera Di Bologna Policlinico S. Orsola - Malpighi
city: Milano
country: Italy
facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia- Padiglione Marcora 2° piano
city: Milano
country: Italy
facility: Ospedale Niguarda " Ca Granda" - SC Ematologia Blocco SUD, Ponti Est, Scala E, 4° piano
city: Monza
country: Italy
facility: Azienda Ospedaliera "S.Gerardo"
city: Napoli
country: Italy
facility: Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli"
city: Novara
country: Italy
facility: S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro
city: Orbassano
country: Italy
facility: Azienda Ospedale S. Luigi at University of Torino
city: Padova
country: Italy
facility: AO di Padova Università degli Studi Padova Dipartimento di Medicina Clinica Medica I - Medicina Interna CLOPD
city: Rimini
country: Italy
facility: Ospedale "Infermi"
city: Roma
country: Italy
facility: Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia
city: Rome
country: Italy
facility: Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore
city: Udine
country: Italy
facility: Clinica Ematologica-Centro Trapianti e Terapie cellulari Azienda Ospedaliero-Universitaria, Udine
city: Verona
country: Italy
facility: Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi
city: Vicenza
country: Italy
facility: Ospedale San Bortolo
Study officials:
affiliation: Clinica Ematologica, DISM, Azienda Ospedaliera Universitaria S. M. Misericordia
name: Francesco Zaja, Pr.
role: STUDY_CHAIR
References: